New York esophageal squamous cell carcinoma-1 and cancer immunotherapy

Immunotherapy. 2015;7(4):411-39. doi: 10.2217/imt.15.3.

Abstract

New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a known cancer testis gene with exceptional immunogenicity and prevalent expression in many cancer types. These characteristics have made it an appropriate vaccine candidate with the potential application against various malignancies. This article reviews recent knowledge about the NY-ESO-1 biology, function, immunogenicity and expression in cancers as well as and the results of clinical trials with this antigen.

Keywords: NY-ESO-1; cancer-testis antigen; immunogenicity; immunotherapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigens, Neoplasm / immunology
  • Antigens, Neoplasm / metabolism*
  • Cancer Vaccines*
  • Carcinoma, Squamous Cell / immunology
  • Carcinoma, Squamous Cell / therapy*
  • Clinical Trials as Topic
  • Esophageal Neoplasms / immunology
  • Esophageal Neoplasms / therapy*
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunotherapy*
  • Membrane Proteins / immunology
  • Membrane Proteins / metabolism*

Substances

  • Antigens, Neoplasm
  • CTAG1B protein, human
  • Cancer Vaccines
  • Membrane Proteins